Digest Network Come funziona
Network
/
Società
Xe
Non verificato

Xencor, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

27 comunicati stampa

Guarda tutti i comunicati
04/03/2026
Mercato del lavoro
Mercato azionario
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Xencor Announces Change to Ultomiris® Royalty Revenue Forecast
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0
25/02/2026
Mercato azionario
Biotecnologia
Salute
Oncologia
Medicina - Varie
Xencor Reports Fourth Quarter and Full Year 2025 Financial Results
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0
23/02/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Xencor to Participate at Upcoming Investor Conferences
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0
08/01/2026
Industria
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0
09/12/2025
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0
10/11/2025
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Salute
Oncologia
Xencor to Participate at Upcoming Investor Conferences
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0
05/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Mercato azionario
Xencor Reports Third Quarter 2025 Financial Results
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0
21/10/2025
Web e Social Network
Telefonia e Varie
Eventi
Industria
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0
14/10/2025
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Web e Social Network
Eventi
Industria
Xencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0
27/08/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Eventi
Web e Social Network
Xencor to Participate at Upcoming Investor Conferences
Fonte
Xencor, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0